相关实验视频
Updated: Jan 17, 2026

08:15
Gastrointestinal Motility Monitor GIMM
Published on: December 1, 2010
31.5K
伊卡里西德II通过抑制巨细胞极化和抑制cGAS-STING通路来改善缓慢过渡性便秘
Ziying Jiang1, Fangxu Yin1, Yaqian Ping1
1Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
European journal of pharmacology
|September 18, 2025
概括
伊卡里西德II (ICS II) 通过减少炎症和保护神经,有效治疗缓慢过渡性便秘 (STC). 它通过抑制cGAS-STING通路和降低M1巨细胞极化而起作用.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缓慢过渡便秘 (STC) 是一种功能性胃肠道疾病,其特征是结肠运动能力受损.
- 病原发生涉及肠道神经系统损伤和免疫失调.
- 伊卡里赛德II (ICS II) 是一种黄类糖化物,具有已知的抗炎,抗氧化和神经保护性质,但其在STC中的作用尚未被探索.
研究的目的:
- 研究Icariside II (ICS II) 对缓慢过渡性便秘 (STC) 的治疗作用.
- 阐明STC中ICS II作用的潜在机制,重点关注肠道巨细胞和cGAS-STING通路.
主要方法:
- 使用了洛佩拉胺诱导的STC的动物模型.
- 药物的疗效通过表型观察,血素和色素染色,免疫光,西部斑点和流动细胞计等方式进行评估.
- 肠道巨细胞和cGAS-STING通路的作用被使用klodronate脂质体和一种STING抑制剂进行了研究.
主要成果:
- ICS II治疗改善了STC症状,包括增加便产量,水分和推进率,并减少了第一次黑暗便排便时间.
- ICS II的使用导致了结肠组织病理的改善,减少了M1型巨细胞的比例,并降低了cGAS-STING通路蛋白的调节.
- 治疗减少了炎症性细胞因子 (IL-1β,IL-6,TNF-α),减少了神经元损伤,增加了神经纤维密度.
结论:
- 在STC的临床前模型中,Icariside II (ICS II) 显示出显著的抗炎和神经保护作用.
- 这些有益效应通过抑制cGAS-STING信号通路和抑制M1巨细胞极化来实现.
- ICS II显示出作为一种新型治疗剂的潜力,用于缓慢过渡性便秘的管理.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
726
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
726
Drugs for Treatment of Diarrhea-Predominant IBS
635
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
635
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
574
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
574
Drugs Affecting GI Tract Motility: Other Laxatives
1.0K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
900
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
900
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
530
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
530

